MedTrace Logo

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

NCT02047656 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2016-04-01

No results posted yet for this study

Summary

This study is designed to enable optimal dose selection of LFF269 for potential future studies by providing additional information about the compounds safety, tolerability, pharmacokinetic and pharmacodynamic profiles.

Conditions

  • Part 1 - Healthy Volunteers
  • Part 2 - Patients With Hypertension

Interventions

DRUG

LFF269

LFF269 capsules twice daily (b.i.d)

DRUG

Placebo to LFF269

Placebo LFF269 b.i.d for 10 days in healthy volunteers

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02047656 on ClinicalTrials.gov